The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Real-world survival in patients with mixed phenotype ATTR-CM treated with tafamidis
In this video, Jonas Wixner, MD, PhD, Umeå University, Umeå, Sweden, discusses the survival outcomes in a real-world cohort of patients with mixed phenotype transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis. Findings show that tafamidis improves survival in both wild-type and variant patients. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
